Association of T-cadherin levels with the response to neoadjuvant chemotherapy in locally advanced breast cancer

Oncotarget. 2017 Feb 21;8(8):13747-13753. doi: 10.18632/oncotarget.14630.

Abstract

Purpose: To examine the association of T-cadherin with pathologic complete response (pCR) after neoadjuvant chemotherapy for locally advanced breast cancer.

Results: T-cadherin expression before and after neoadjuvant chemotherapy was similar (P = 0.162). The multivariable analysis indicated that negative T-cadherin expression was independently associated with pCR after neoadjuvant TAC chemotherapy (P = 0.001).

Materials and methods: A total of 136 patients with locally advanced breast cancer received four cycles of neoadjuvant TAC chemotherapy (docetaxel + epirubicin + cyclophosphamide), followed by surgery. T-cadherin, estrogen receptor (ER), progesterone receptor (PR), HER-2, and Ki-67 were analyzed by immunohistochemistry. The association between T-cadherin expression and pCR after neoadjuvant chemotherapy was analyzed using multivariable logistic analysis.

Conclusions: Negative T-cadherin expression before and after neoadjuvant chemotherapy for locally advanced breast cancer was similar. T-cadherin could be considered an independent factor associated with the efficacy of such therapy.

Keywords: T-cadherin; locally advanced breast cancer; neoadjuvant chemotherapy.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism*
  • Breast Neoplasms / pathology
  • Cadherins / biosynthesis*
  • Chemotherapy, Adjuvant
  • Cohort Studies
  • Female
  • Humans
  • Middle Aged
  • Neoadjuvant Therapy

Substances

  • Cadherins
  • H-cadherin